The medical community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s showing significant promise in clinical trials for managing obesity. Unlike some current weight loss solutions, retatrutide appears to deliver a more substantial decrease in body size and benefit metabolic function, particularly conc… Read More